

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, Dale B.
		Art Unit	1649
		Examiner Name	Kolker, Daniel E.
Sheet	1	of	5
		Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1103	2008/0145373	06-19-2008	Arumugham et al.	
	1096	2007/0021454 A1	01-25-2007	Coburn et al.	
	1099	2006/0057701 A1	03-16-2006	Rosenthal et al.	
	1098	2005/0090648 A1	04-28-2005	Tsurushita et al.	
	1101	2003/0054484 A1	03-20-2003	Fong et al.	
	1131	6,015,662	01-18-2000	Hackett et al.	
	1148	5,773,007	06-30-1998	Penney et al.	
	1147	5,723,130	03-03-1998	Hancock et al.	

U.S. PATENT APPLICATIONS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1129	11/842,085	08-20-2007	Schenk	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY			
	1102	EP	1 690 547	A1	08-16-1998	8/16/2006		<input type="checkbox"/>
	1135	WO	08/131298	A3	12-18-2008			<input type="checkbox"/>
	1107	WO	08/131298	A2	10-30-2008			<input type="checkbox"/>
	1133	WO	06/042158	A	04-20-2006			<input type="checkbox"/>
	1146	WO	05/035753	A	04-21-2005			<input type="checkbox"/>
	1145	WO	87/02671	A	05-07-1987			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 5

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/D.K./	1120	ARMOUR et al., "Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities," <i>J. Immunol.</i> 29:2613-2624 (1999).	<input type="checkbox"/>
/D.K./	1117	AVIS, "Parenteral Preparations," <i>Remington's Pharmaceutical Sciences</i> , 17:1518-1519 (1985).	<input type="checkbox"/>
/D.K./	1138	BRINKMAN, "Splice Variants as Cancer Biomarkers," <i>Clinical Biochemistry</i> , 37(7):584-594 (2004).	<input type="checkbox"/>
/D.K./	1110	CHEN et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen," <i>J. Mol. Biol.</i> 293:865-881 (1999).	<input type="checkbox"/>
/D.K./	1142	CHOI et al., "A Generic Intron Increases Gene Expression in Transgenic Mice," <i>Molecular and Cellular Biology</i> , 11(6):3070-3074 (1991).	<input type="checkbox"/>
/D.K./	1132	Corcoran et al., "Overexpression of hAPPswe Impairs Rewarded Alternation and Contextual Fear Conditioning in a Transgenic Mouse Model of Alzheimer's Disease," <i>Learn Mem.</i> 9(5):243-252:2000.	<input type="checkbox"/>
/D.K./	1144	DATABASE Geneseq, "Nucleotide Sequence of a Variable Heavy Chain of IgG4," EBI Accession No. GSN:ADZ51216 (2005).	<input type="checkbox"/>
/D.K./	1100	Dialog/Derwent, Abstract of WPI Acc No: 1995-261292/199534: Novel monoclonal antibody against human high-affinity IgE receptor – and DNA fragment encoding the MAB, for the specific identification of human Fc-epsilon RI, Derwent WPI database (1995).	<input type="checkbox"/>
/D.K./	1137	Extended European Search Report of 12/18/08 for European Application 05812436.6-1212.	<input type="checkbox"/>
/D.K./	1136	European Examination Report of 09/23/2008 for European Application 04776252.1-2405.	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, Dale B.
		Art Unit	1649
		Examiner Name	Kolker, Daniel E.
Sheet	3	of	5
		Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/D.K./	1130	European Examination Report as part of 12-08-2008 communication for European Application 04720353.4	<input type="checkbox"/>
/D.K./	1134	European Examination Report of 11/20/2008 for European Application 08011409.3	<input type="checkbox"/>
/D.K./	1150	Family and legal status of EP0613007, Inpadoc Search (2009).	<input type="checkbox"/>
/D.K./	1097	FRAGIONE et al., "Familial cerebral amyloid angiopathy related to stroke and dementia. <u>Amyloid</u> , 8(Suppl 1):36-42 (2001), abstract only.	<input type="checkbox"/>
/D.K./	1118	HEZAREH et al., "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>Journal of Virology</u> , 24(75):12161-12168 (2001).	<input type="checkbox"/>
	1127	JANEWAY et al., <u>Immunobiology</u> , 2 nd edition, pages 8-18-8-19 (1997)	<input type="checkbox"/>
/D.K./	1121	MANN et al., "Atypical Amyloid (ABeta) Deposition in the cerebellum in Alzheimer's Disease: An Immunohistochemical Study Using End-Specific ABeta Monoclonal Antibodies," <u>ACTA Neuropathologica</u> , 91:647-653 (1996).	<input type="checkbox"/>
/D.K./	1122	MANN et al., "Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene," <u>The American Journal of Pathology</u> APR, 4(148): 1257-1266 (1996).	<input type="checkbox"/>
/D.K./	1139	MYERS et. al., "Targeting Immune Effector Molecules to Human Tumor Cells Through Genetic Delivery of 5T4-Specific SCFV Fusion Proteins," <u>Cancer Gene Therapy</u> , 9(11):884-896 (2002).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known Application Number 09/322,289 Filing Date May 28, 1999 First Named Inventor Schenk, Dale B. Art Unit 1649 Examiner Name Kolker, Daniel E. Attorney Docket Number 15270J-004740US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	4	of	5		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
/D.K./	1108	PASCALIS et al., "Grafting of "Abbreviated" Complementarity-Determining Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," <u>The Journal of Immunology</u> , 169:3076-3084 (2002).	<input type="checkbox"/>		
/D.K./	1149	QU et al., "Aβ ₄₂ gene Vaccine Prevents Aβ ₄₂ deposition in brain of Double Transgenic Mice," <u>J. Neurological Sciences</u> , 260:204-213 (2007).	<input type="checkbox"/>		
/D.K./	1141	ROBBINS et al., "The Intronic Region of an Incompletely Spliced gp100 Gene Transcript Encodes an Epitope Recognized by Melanoma-Reactive Tumor-Infiltrating Lymphocytes," <u>Journal of Immunology</u> , 159(1):303-308 (1997).	<input type="checkbox"/>		
/D.K./	1140	SEABROOK et al., "Species-specific Immune response to Immunization with Human Versus rodent Abeta Peptide," <u>Neurobiology of Aging</u> , 25(9) 1141-1151 (2004)	<input type="checkbox"/>		
/D.K./	1123	SCHMIDT et al., "Monoclonal Antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains," <u>The American Journal of Pathology</u> , 1(151):69-80 (1997).	<input type="checkbox"/>		
/D.K./	1119	Shepherd et al., "The design of the humanized antibody," <u>Monoclonal Antibodies: A Practical Approach</u> 58-66 (2000)	<input type="checkbox"/>		
/D.K./	1104	SIDHU, "Page display in pharmaceutical biotechnology," <u>Current Opinoin in Biotechnology</u> , 11:610-616 (2000).	<input type="checkbox"/>		
/D.K./	1105	SMITH et al., "Phage Display," <u>Chemical Reviews, American Chemical Society</u> , 97(2):391-410 (1997).	<input type="checkbox"/>		
/D.K./	1128	STUDNICKA et al., "Human-engineered monoclnal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," <u>Protein Eng.</u> , 7(6):805-814 (1994), Abstract only.	<input type="checkbox"/>		
/D.K./	1124	TAMAOKA et al., "Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH)," <u>Neurobiology of Aging</u> , 3(17):405-414 (1996).	<input type="checkbox"/>		
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kolker, Daniel E.	
Sheet	5	of	5	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/D.K./	1112	U.S. Application No. 09/316,387, Office Action mailed 09/10/2007.		<input type="checkbox"/>
/D.K./	1113	U.S. Application No. 09/316,387, Response to 06-20-2005 Office Action filed 12-20-2005.		<input type="checkbox"/>
/D.K./	1114	U.S. Application No. 09/316,387, Declaration of Solomon, Hrmic, and Wall under 37 C.F.R. § 1.131 filed 03-06-2006.		<input type="checkbox"/>
/D.K./	1115	U.S. Application No. 09/316,387, Office Action mailed 06/20/2005.		<input type="checkbox"/>
/D.K./	1109	Vajdos et al., "Comprehensive Functional Maps of the Antigen-binding site of an Anti_ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis," <i>J. Mol. Biol.</i> , 320:415-428 (2002).		<input type="checkbox"/>
/D.K./	1143	WARD et al., "Spontaneous Deletions In IG Heavy Chain Genes Flanking Sequences Influence Splice Site Selection <i>Nucleic Acids Research</i> ," 19(23): 6475-6480 (1991).		<input type="checkbox"/>
/D.K./	1106	WILSON et al., "Phage display: applications, innovations, and issues in phage and host biology," <i>Can. J. Microbiol.</i> , 44:313-329 (1998).		<input type="checkbox"/>
/D.K./	1111	WU et al., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," <i>J. Mol. Biol.</i> , 294:151-162 (1999).		<input type="checkbox"/>
/D.K./	1125	YANAGISAWA K et al., "Amyloid BETA-protein (Alpha-Beta) associated with lipid molecules: immunoreactivity distinct from that of soluble Alpha-Beta," <i>FEBS Letters</i> , 1(420): 43-46 (1997).		<input type="checkbox"/>
/D.K./	1126	YANG et al., "Monoclonal Antibody to the C-terminus of Beta-Amyloid," <i>Neuroreport</i> , 16(5):2117-2120 (1994).		<input type="checkbox"/>

Examiner Signature	/Daniel Kolker/	Date Considered	06/03/2009
---------------------------	-----------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.